FTC/Industry Showdown Over Orange Book Patent Listings Could Come In 2024

 
• By Brenda Sandburg

GlaxoSmithKline, Amneal and Kaleo delist patents on inhalers and autoinjectors in drug-device combination products in response to FTC criticism. But AstraZeneca, Boehringer Ingelheim, and Teva hold firm, teeing up legal battles if the Commission takes enforcement action.

ftc orange book patents
Battles over Orange Book patent listings seem likely as companies reject FTC claims of improper listings. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from Pink Sheet Perspectives

More from Pink Sheet